Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 4
2005 5
2007 3
2008 3
2010 4
2011 5
2012 2
2013 11
2014 17
2015 9
2016 7
2017 2
2018 5
2019 10
2020 14
2021 14
2022 18
2023 16
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B.
Tamaki N, Higuchi M, Keitoku T, Yamazaki Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Okada R, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Tsuchiya K, Nakanishi H, Kanto T, Kurosaki M, Izumi N. Tamaki N, et al. Among authors: tsuchiya k. JGH Open. 2024 Apr 25;8(4):e13067. doi: 10.1002/jgh3.13067. eCollection 2024 Apr. JGH Open. 2024. PMID: 38665298 Free PMC article.
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Suzuki K, Yasui Y, Tsuchiya K, Matsumoto H, Yamazaki Y, Uchihara N, Tanaka Y, Miyamoto H, Yamada-Shimizu M, Keitoku T, Okada R, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Suzuki K, et al. Among authors: tsuchiya k. J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532. Online ahead of print. J Gastroenterol Hepatol. 2024. PMID: 38494668
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Suzuki K, Tamaki N, Kurosaki M, Takahashi Y, Yamazaki Y, Uchihara N, Tanaka Y, Miyamoto H, Yamada M, Keitoku T, Okada R, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Tsuchiya K, Nakanishi H, Izumi N. Suzuki K, et al. Among authors: tsuchiya k. Hepatol Res. 2024 Jan 17. doi: 10.1111/hepr.14011. Online ahead of print. Hepatol Res. 2024. PMID: 38234088
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N. Kudo M, et al. Among authors: tsuchiya k. Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep. Liver Cancer. 2023. PMID: 37901197 Free PMC article.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.
Kirino S, Tamaki N, Kurosaki M, Takahashi Y, Higuchi M, Itakura Y, Tanaka Y, Inada K, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Kirino S, et al. Among authors: tsuchiya k. Quant Imaging Med Surg. 2023 Oct 1;13(10):6493-6502. doi: 10.21037/qims-23-511. Epub 2023 Aug 28. Quant Imaging Med Surg. 2023. PMID: 37869309 Free PMC article.
A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Yamada-Shimizu M, Tamaki N, Kurosaki M, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Nobusawa T, Matsumoto H, Keitoku T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Yamada-Shimizu M, et al. Among authors: tsuchiya k. Intern Med. 2023 Sep 29. doi: 10.2169/internalmedicine.2248-23. Online ahead of print. Intern Med. 2023. PMID: 37779070 Free article.
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.
Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J, Lencioni R. Kudo M, et al. Among authors: tsuchiya k. Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37767068 Free PMC article.
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.
Ishido S, Tamaki N, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Izumi N. Ishido S, et al. Among authors: tsuchiya k. JGH Open. 2023 Jul 21;7(8):567-571. doi: 10.1002/jgh3.12950. eCollection 2023 Aug. JGH Open. 2023. PMID: 37649865 Free PMC article.
135 results